ADMA Biologics Raises 2026 Guidance, Projects Strong Long-Term Growth to $1.1B Revenue by 2029
ADMA sits 34% above its 52-week low of $13.5.
Summary
ADMA Biologics announced preliminary unaudited full year 2025 revenue meeting guidance, and significantly raised its financial outlook for 2026 and beyond, projecting over $1.1 billion in annual revenue by 2029.
Key Events · Earnings and Guidance · ADMA
-
Raised 2026 Financial Guidance
The company increased its expected total revenue for fiscal year 2026 to approximately $635 million (up from $630 million) and Adjusted EBITDA to approximately $360 million (up from $355 million).
-
Strong Long-Term Growth Targets
ADMA introduced new fiscal year 2027 guidance, projecting approximately $775 million in total revenue and $455 million in Adjusted EBITDA. It also targets over $1.1 billion in annual revenue and $700 million in Adjusted EBITDA by fiscal year 2029.
-
Strategic Operational Enhancements
ADMA successfully implemented yield-enhanced production, with 2026 expected to be the first full year of monetizing this. The company also repositioned its plasma collection network, divesting three centers for $12 million and securing long-term plasma supply agreements to enhance margins and supply visibility.
-
Solid 2025 Performance
Preliminary unaudited full year 2025 total revenue is estimated at $510-$511 million, meeting or exceeding prior guidance. The company ended 2025 with approximately $88 million in cash, including $40 million in operating cash flow generated in Q4 2025.
Analysis · ADMA · Life Sciences
ADMA Biologics delivered a comprehensive positive update, significantly raising its financial outlook for 2026 and providing robust long-term targets through 2029. The increased revenue and Adjusted EBITDA guidance for 2026, coupled with new, strong projections for 2027 and a target of over $1.1 billion in annual revenue by 2029, signals accelerating growth and expanding profitability. Strategic operational improvements, such as the successful implementation of yield-enhanced production and the repositioning of its plasma network, are expected to drive margin expansion and ensure long-term supply. These factors collectively indicate strong business momentum and management's confidence in future performance.
At the time of this filing, ADMA was trading at $18.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $13.50 to $25.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.